Acute Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension: Clinical and Serial CT Pulmonary Angiographic Features

An Junho,Nam Yoojin,Cho Hyoun,Chang Jeonga,Kim Duk-Kyung,Lee Kyung Soo 대한의학회 2022 Journal of Korean medical science Vol.37 No.10

In acute pulmonary embolism (PE), circulatory failure and systemic hypotension are important clinically for predicting poor prognosis. While pulmonary artery (PA) clot loads can be an indicator of the severity of current episode of PE or treatment effectiveness, they may not be used directly as an indicator of right ventricular (RV) failure or patient death. In other words, pulmonary vascular resistance or patient prognosis may not be determined only with mechanical obstruction of PAs and their branches by intravascular clot loads on computed tomography pulmonary angiography (CTPA), but determined also with vasoactive amines, reflex PA vasoconstriction, and systemic arterial hypoxemia occurring during acute PE. Large RV diameter with RV/left ventricle (LV) ratio > 1.0 and/or the presence of occlusive clot and pulmonary infarction on initial CTPA, and clinically determined high baseline PA pressure and RV dysfunction are independent predictors of oncoming chronic thromboembolic pulmonary hypertension (CTEPH). In this pictorial review, authors aimed to demonstrate clinical and serial CTPA features in patients with acute massive and submassive PE and to disclose acute CTPA and clinical features that are related to the prediction of oncoming CTEPH.

NoSQL based Web Service System for Sharing of Emotion Information in Cloud Computing

Junho Jung,Jeong Byun,DongKeun Kim3 보안공학연구지원센터 2016 International Journal of Software Engineering and Vol.10 No.3

We present the No-SQL based Web service system for sharing of emotion information regarding the individual emotional states and location information of users using by a MongoDB in cloud computing environments. Pre-processed emotion information represents the individual emotional states categorized as a nine domain based on physiological signals recognition within the database system. However, in order to present individual emotional states regarding to pre-processed user’s emotional states and locations on a Web-based map, the computational overload with large amount of data for a location-query process is to be solved for support sharing Web services. Meanwhile, previous RDBMS-based systems are inadequate due to insufficient scalability and processing time of data processing nodes. Therefore, in this paper, we have designed and implemented an emotion sharing web service by reducing the load on the system using NoSQL database. In addition, it was confirmed that it is possible to effectively utilize resources and visualized by using Google’s FusionTable and it is possible to share on a Web map.

Preclinical development of a humanized neutralizing antibody targeting HGF

Kim, Hyori,Hong, Sung Hee,Kim, Jung Yong,Kim, In-Chull,Park, Young-Whan,Lee, Song-Jae,Song, Seong-Won,Kim, Jung Ju,Park, Gunwoo,Kim, Tae Min,Kim, Yun-Hee,Park, Jong Bae,Chung, Junho,Kim, In-Hoo Nature Publishing Group 2017 Experimental and molecular medicine Vol.49 No.3

<P>Hepatocyte growth factor (HGF) and its receptor, cMET, play critical roles in cell proliferation, angiogenesis and invasion in a wide variety of cancers. We therefore examined the anti-tumor activity of the humanized monoclonal anti-HGF antibody, YYB-101, in nude mice bearing human glioblastoma xenografts as a single agent or in combination with temozolomide. HGF neutralization, The extracellular signal-related kinases 1 and 2 (ERK1/2) phosphorylation, and HGF-induced scattering were assessed in HGF-expressing cell lines treated with YYB-101. To support clinical development, we also evaluated the preclinical pharmacokinetics and toxicokinetics in cynomolgus monkeys, and human and cynomolgus monkey tissue was stained with YYB-101 to test tissue cross-reactivity. We found that YYB-101 inhibited cMET activation <I>in vitro</I> and suppressed tumor growth in the orthotopic mouse model of human glioblastoma. Combination treatment with YYB-101 and temozolomide decreased tumor growth and increased overall survival compared with the effects of either agent alone. Five cancer-related genes (TMEM119, FST, RSPO3, ROS1 and NBL1) were overexpressed in YYB-101-treated mice that showed tumor regrowth. In the tissue cross-reactivity assay, critical cross-reactivity was not observed. The terminal elimination half-life was 21.7 days. Taken together, the <I>in vitro</I> and <I>in vivo</I> data demonstrated the anti-tumor efficacy of YYB-101, which appeared to be mediated by blocking the HGF/cMET interaction. The preclinical pharmacokinetics, toxicokinetics and tissue cross-reactivity data support the clinical development of YYB-101 for advanced cancer.</P>

The Characteristics of CIGS Thin-Film Solar Cells Using Sputtering Based Two-Step Process

Young-Ill Kim,Dong-Hwan Jeon,Si-Nae Park,Se-Yun Kim,Dae-Hwan Kim,Jin-Kyu Kang,Shi-Joon Sung,Juran Kim,William Jo,Hyesun Yoo,JunHo Kim,Dae-Hwan Kim,Kee-Jeong Yang 한국신재생에너지학회 2019 AFORE Vol.2019 No.11

Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy

Lim, Jae Seok,Kim, Woo-il,Kang, Hoon-Chul,Kim, Se Hoon,Park, Ah Hyung,Park, Eun Kyung,Cho, Young-Wook,Kim, Sangwoo,Kim, Ho Min,Kim, Jeong A,Kim, Junho,Rhee, Hwanseok,Kang, Seok-Gu,Kim, Heung Dong,Kim, Nature Publishing Group 2015 Nature medicine Vol. No.

Focal cortical dysplasia type II (FCDII) is a sporadic developmental malformation of the cerebral cortex characterized by dysmorphic neurons, dyslamination and medically refractory epilepsy. It has been hypothesized that FCD is caused by somatic mutations in affected regions. Here, we used deep whole-exome sequencing (read depth, 412–668×) validated by site-specific amplicon sequencing (100–347,499×) in paired brain-blood DNA from four subjects with FCDII and uncovered a de novo brain somatic mutation, mechanistic target of rapamycin (MTOR) c.7280T>C (p.Leu2427Pro) in two subjects. Deep sequencing of the MTOR gene in an additional 73 subjects with FCDII using hybrid capture and PCR amplicon sequencing identified eight different somatic missense mutations found in multiple brain tissue samples of ten subjects. The identified mutations accounted for 15.6% of all subjects with FCDII studied (12 of 77). The identified mutations induced the hyperactivation of mTOR kinase. Focal cortical expression of mutant MTOR by in utero electroporation in mice was sufficient to disrupt neuronal migration and cause spontaneous seizures and cytomegalic neurons. Inhibition of mTOR with rapamycin suppressed cytomegalic neurons and epileptic seizures. This study provides, to our knowledge, the first evidence that brain somatic activating mutations in MTOR cause FCD and identifies mTOR as a treatment target for intractable epilepsy in FCD.

Correlations Between Electrically Quantified Pain Degree, Subjectively Assessed Visual Analogue Scale, and the McGill Pain Questionnaire: A Pilot Study

Junho Kim,Kyung Soo Lee,Sangwon Kong,Taikon Kim,Mi Jung Kim,박시복,Kyu Hoon Lee 대한재활의학회 2014 Annals of Rehabilitation Medicine Vol.38 No.5

Objective To evaluate the clinical utility of the electrically calculated quantitative pain degree (QPD) and to correlate it with subjective assessments of pain degree including a visual analogue scale (VAS) and the McGill Pain Questionnaire (MPQ).Methods We recruited 25 patients with low back pain. Of them, 21 patients suffered from low back pain for more than 3 months. The QPD was calculated using the PainVision (PV, PS-2100; Nipro Co., Osaka, Japan). We applied electrodes to the medial forearm of the subjects and the electrical stimulus was amplified sequentially. Minimum perceived current (MPC) and pain equivalent current (PEC) were defined as minimum electrical stimulation that could be sensed by the subject and electrical stimulation that could trigger actual pain itself. To eliminate individual differences, we defined QPD as the following: QPD=PEC−MPC/MPC. We scored pre-treatment QPD three times at admission and post-treatment QPD once at discharge. The VAS, MPQ, and QPD were evaluated and correlations between the scales were analyzed.Results Result showed significant test-retest reliability (ICC=0.967, p<0.001) and the correlation between QDP and MPQ was significant (at admission SRCC=0.619 and p=0.001; at discharge SRCC=0.628, p=0.001). However, the correlation between QPD and VAS was not significant (at admission SRCC=0.240, p=0.248; at discharge SRCC=0.289, p=0.161).Conclusion Numerical values measured with PV showed consistent results with repeated calculations. Electrically measured QPD showed an excellent correlation with MPQ but not with VAS. These results demonstrate that PV is a significantly reliable device for quantifying the intensity of low back pain.

SoloDel: a probabilistic model for detecting low-frequent somatic deletions from unmatched sequencing data

Kim, Junho,Kim, Sanghyeon,Nam, Hojung,Kim, Sangwoo,Lee, Doheon Oxford University Press 2015 Bioinformatics Vol.31 No.19

<P><B>Motivation:</B> Finding somatic mutations from massively parallel sequencing data is becoming a standard process in genome-based biomedical studies. There are a number of robust methods developed for detecting somatic single nucleotide variations However, detection of somatic copy number alteration has been substantially less explored and remains vulnerable to frequently raised sampling issues: low frequency in cell population and absence of the matched control samples.</P><P><B>Results:</B> We developed a novel computational method SoloDel that accurately classifies low-frequent somatic deletions from germline ones with or without matched control samples. We first constructed a probabilistic, somatic mutation progression model that describes the occurrence and propagation of the event in the cellular lineage of the sample. We then built a Gaussian mixture model to represent the mixed population of somatic and germline deletions. Parameters of the mixture model could be estimated using the expectation-maximization algorithm with the observed distribution of read-depth ratios at the points of discordant-read based initial deletion calls. Combined with conventional structural variation caller, SoloDel greatly increased the accuracy in classifying somatic mutations. Even without control, SoloDel maintained a comparable performance in a wide range of mutated subpopulation size (10–70%). SoloDel could also successfully recall experimentally validated somatic deletions from previously reported neuropsychiatric whole-genome sequencing data.</P><P><B>Availability and implementation:</B> Java-based implementation of the method is available at http://sourceforge.net/projects/solodel/</P><P><B>Contact:</B> swkim@yuhs.ac or dhlee@biosoft.kaist.ac.kr</P><P><B>Supplementary information:</B> Supplementary data are available at <I>Bioinformatics</I> online.</P>

Qualitative and quantitative comparison of N-glycans between pig endothelial and islet cells by high-performance liquid chromatography and mass spectrometry-based strategy

Kim, Yun-Gon,Gil, Geun-Cheol,Jang, Kyung-Soon,Lee, Sukmook,Kim, Hyoung-Il,Kim, Jung-Sik,Chung, Junho,Park, Chung-Gyu,Harvey, David J.,Kim, Byung-Gee John Wiley Sons, Ltd. 2009 Journal of mass spectrometry Vol.44 No.7

<P>N-glycan structures released from miniature pig endothelial and islet cells were determined by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF), negative ion electrospray ionization (ESI) MS/MS and normal-phase high performance liquid chromatography (NP-HPLC) combined with exoglycosidase digestion. Totally, the identified structures were 181 N-glycans including 129 sialylated and 18 α-galactosylated glycans from pig endothelial cells and 80 N-glycans including 41 sialylated and one α-galactosylated glycans from pig islet cells. The quantity of the α-galactosylated glycans from pig islet cells was certainly neglectable compared to pig endothelial cells. A number of NeuGc-terminated N-glycans (80 from pig endothelial cells and 13 from pig islet cells) are newly detected by our mass spectrometric strategies. The detailed structural information will be a matter of great interest in organ or cell xenotransplantation using α 1,3-galactosyltransferase gene-knockout (GalT-KO) pig. Copyright © 2009 John Wiley & Sons, Ltd.</P>

Clinical outcomes of omaliumab treatment on cholinergic urticaria

( Junho Kim ),( Donghyun Kim ),( Young Joo Kim ),( Da Woon Sim ),( Hye Jung Park ),( Kyung Hee Park ),( Jung-won Park ),( Jae-hyun Lee ) 대한내과학회 2015 대한내과학회 추계학술대회 Vol.2015 No.1

Background: Cholinergic urticaria is one of the inducible urticaria and it’s symptoms are provocated by a rise in body temperature. There are some conflicting case reports of omalizumab effect on cholinergic urticaria. Objective: The aim of this study was to evaluate the clinical effect of omalizumab on refractory cholinergic urticaria. Methods: We performed a single center, retrospective study. Since January 2014 to July 2015, 13 patients were treated with omalizumab after failure of antihistamine. Telephone survey including visual analog scale (VAS) and urticaria control test (UCT, 0-16, high score means better control) is performed and response is defined as complete (post treatment VAS≤2 & UCT≥12), partial and no response (post treatment VAS≤2 & UCT≥12). Results: 12 men and 1 women, with a mean age and disease duration of 28 years and 53 months, were included. All patients had at least 5 aggravating factors and 4 patients had chronic spontaneous urticaria and 6 patients had house dust mite sensitization on MAST. After omalizumab, VAS decreased from 8.23±0.93 to 3.69±2.56 (p<0.0001) and UCT increased from 3.77±1.42 to 9.77±3.66 (p> 0.0001) and 5 patients had complete response, while 5 and 3 patients had partial and no response. In responders, the number of injection, injection interval and serum eosinophil count were statistically significant higher than no responders. Conclusions: Our result shows that omalizumab might be useful in refractory cholinergic urticaria. Clinician should consider omalizumab in patients with antihistamine failure.

Stable isotopic labeling-based quantitative targeted glycomics (i-QTaG).

Kim, Kyoung-Jin,Kim, Yoon-Woo,Kim, Yun-Gon,Park, Hae-Min,Jin, Jang Mi,Hwan Kim, Young,Yang, Yung-Hun,Kyu Lee, Jun,Chung, Junho,Lee, Sun-Gu,Saghatelian, Alan American Institute of Chemical Engineers ; America 2015 Biotechnology progress Vol.31 No.3

<P>Mass spectrometry (MS) analysis combined with stable isotopic labeling is a promising method for the relative quantification of aberrant glycosylation in diseases and disorders. We developed a stable isotopic labeling-based quantitative targeted glycomics (i-QTaG) technique for the comparative and quantitative analysis of total N-glycans using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). We established the analytical procedure with the chemical derivatizations (i.e., sialic acid neutralization and stable isotopic labeling) of N-glycans using a model glycoprotein (bovine fetuin). Moreover, the i-QTaG using MALDI-TOF MS was evaluated with various molar ratios (1:1, 1:2, 1:5) of (13) C6 /(12) C6 -2-aminobenzoic acid-labeled glycans from normal human serum. Finally, this method was applied to direct comparison of the total N-glycan profiles between normal human sera (n = 8) and prostate cancer patient sera (n = 17). The intensities of the N-glycan peaks from i-QTaG method showed a good linearity (R(2) > 0.99) with the amount of the bovine fetuin glycoproteins. The ratios of relative intensity between the isotopically 2-AA labeled N-glycans were close to the theoretical molar ratios (1:1, 1:2, 1:5). We also demonstrated that the up-regulation of the Lewis antigen (~82%) in sera from prostate cancer patients. In this proof-of-concept study, we demonstrated that the i-QTaG method, which enables to achieve a reliable comparative quantitation of total N-glycans via MALDI-TOF MS analysis, has the potential to diagnose and monitor alterations in glycosylation associated with disease states or biotherapeutics.</P>